Patents Issued in December 21, 2017
-
Publication number: 20170362240Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.Type: ApplicationFiled: December 4, 2015Publication date: December 21, 2017Applicants: ARRAY BIOPHARMA INC., CELGENE CORPORATIONInventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
-
Publication number: 20170362241Abstract: The present invention relates to compounds of formula(I), a process for their production and their use in electronic devices, especially electroluminescent devices. When used as charge transport material and/or host material for phosphorescent emitters in electroluminescent devices, the compounds of formula I may provide improved efficiency and reduced driving voltage of electroluminescent devices.Type: ApplicationFiled: December 15, 2015Publication date: December 21, 2017Applicant: Idemitsu Kosan Co., Ltd.Inventors: Yuichi NISHIMAE, Julia KOHLSTEDT, Thomas SCHAEFER, Hideaki NAGASHIMA
-
Publication number: 20170362242Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: ApplicationFiled: December 17, 2015Publication date: December 21, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, ABDUL-BASIT ALHASSAN, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JYHSHING WANG, WENSHENG YU, JIAQIANG CAI, SHILAN LIU, DAHAI WANG, HAO WU, CHUNDAO YANG
-
Publication number: 20170362243Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: ApplicationFiled: December 17, 2015Publication date: December 21, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JYHSHING WANG, SHILAN LIU
-
Publication number: 20170362244Abstract: The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.Type: ApplicationFiled: June 30, 2017Publication date: December 21, 2017Inventors: Kerim Babaoglu, Constantine G. Boojamra, Eugene J. Eisenberg, Hon Chung Hui, Richard L. Mackman, Jay P. Parrish, Michael Sangi, Oliver L. Saunders, Dustin Siegel, David Sperandio, Hai Yang
-
Publication number: 20170362245Abstract: The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.Type: ApplicationFiled: August 7, 2017Publication date: December 21, 2017Inventors: Liangxing Wu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang
-
Publication number: 20170362246Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Inventors: Joseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
-
Publication number: 20170362247Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.Type: ApplicationFiled: August 21, 2017Publication date: December 21, 2017Inventors: Mathew M. MULHERN, Lars Fredrick NORDSTROEM
-
Publication number: 20170362248Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminopyrimidinone compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.Type: ApplicationFiled: November 20, 2015Publication date: December 21, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Xing Dai, Jared N. Cumming, Hong Liu, Jack D. Scott
-
Publication number: 20170362249Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.Type: ApplicationFiled: May 26, 2017Publication date: December 21, 2017Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
-
Publication number: 20170362250Abstract: Compounds of formula (II): wherein R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.Type: ApplicationFiled: August 14, 2017Publication date: December 21, 2017Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
-
Publication number: 20170362251Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.Type: ApplicationFiled: June 29, 2017Publication date: December 21, 2017Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Chenggeng Qian
-
Publication number: 20170362252Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: ApplicationFiled: December 4, 2015Publication date: December 21, 2017Inventors: Thomas H. Graham, Mark W. Embrey, Abbas Walji, Sherman T. Waddell
-
Publication number: 20170362253Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.Type: ApplicationFiled: June 19, 2017Publication date: December 21, 2017Inventors: Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
-
Publication number: 20170362254Abstract: The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML). A compound comprising Formula (1) wherein: Z is independently selected from the group consisting of CH2, O, C(O), and CH, wherein when Z is CH, Z is connected to Y via a double bond and Y is N.Type: ApplicationFiled: December 3, 2015Publication date: December 21, 2017Inventors: Venumadhav Janganati, Peter Crooks, Narsimha Reddy Penthala, Craig Jordan, Shobanbabu Bommagani, Jessica Ponder
-
Publication number: 20170362255Abstract: An aspect of the present disclosure is a nanocrystal that includes a nanocrystal core and a ligand coordinated to a surface of the nanocrystal core, where the ligand includes a functionalized aromatic molecule. In some embodiments of the present disclosure, the functionalized aromatic molecule may include at least one of cinnamic acid (CAH) and/or a functionalized CAH molecule.Type: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Inventors: Matthew C. Beard, Daniel McCray Kroupa, Alan Sellinger
-
Publication number: 20170362256Abstract: A method for forming a modified surface comprising (1) on a substrate is provided wherein a reactive groups on the surface is condensed with alcohols, thiols, silanes or phosphonic acid in the presence of microwave energy.Type: ApplicationFiled: November 24, 2015Publication date: December 21, 2017Inventors: Byron D. Gates, Woohyuk Lee
-
Publication number: 20170362257Abstract: Provided herein is a multifunctional particle and methods of forming the same. The multifunctional particle includes a surface of the particle; a first moiety coupled to the surface and having at least one substantially hydrophobic appendage; and a second moiety coupled to the surface and having at least one appendage comprising a reactive functional group and a substantially hydrophilic repeating unit, whereby the particle is substantially superhydrophobic as a result of the substantially hydrophobic appendage, chemically reactive as a result of the reactive functional group, and migratory to a surface of a substantially hydrophobic matrix in which the particle may be included as a result of the substantially hydrophilic repeating unit. Additionally, antimicrobial functional groups may be coupled to the surface.Type: ApplicationFiled: December 7, 2015Publication date: December 21, 2017Inventor: Peter Craig Venema
-
Publication number: 20170362258Abstract: System, including methods and compositions, for making and using emulsions that include a silicone oil and a silicone surfactant. The emulsions may include aqueous droplets disposed in a continuous phase that includes a silicone oil and a silicone surfactant. The aqueous droplets may contain an analyte, optionally at partial occupancy, and/or a luminescent (e.g., photoluminescent) reporter. An assay of the analyte may be performed with the droplets. In some cases, signals may be detected from the droplets, and a characteristic of the analyte, such as an analyte level or activity, may be determined based on the signals.Type: ApplicationFiled: September 6, 2017Publication date: December 21, 2017Inventors: Erin R. Chia, Amy L. Hiddessen, Benjamin J. Hindson, Adam Lowe, Chunxiao Han
-
Publication number: 20170362259Abstract: An improved process for making a compound B of the structure wherein n, R1, R2, and R3 are as defined in the specification. Compound B can be used to make tubulysin analogs that are, in turn, useful as anti-cancer agents, particularly when deployed in an antibody-drug conjugate.Type: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Inventors: Adrian ORTIZ, Carlos A. GUERRERO, Bin ZHENG, Jason J. ZHU, Michael Anthony SCHMIDT, Michael R. LUZUNG, Martin D. EASTGATE
-
Publication number: 20170362260Abstract: In one aspect, the invention relates to compounds having the formula X: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: May 8, 2017Publication date: December 21, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Adam D. Hughes, Melissa Fleury
-
Publication number: 20170362261Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.Type: ApplicationFiled: December 11, 2015Publication date: December 21, 2017Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Xingzhou LI, Wu ZHONG, Zhibing ZHENG, Junhai XIAO, Xinbo ZHOU, Yunde XIE, Xiaokui WANG, Lili WANG, Wei CHEN, Fei XIE
-
Publication number: 20170362262Abstract: A process for preparing halogenated azaindole compounds makes use of a brominating agent PyBroP, together with a dehydrating agent BSA to enhance the selectivity and improve the yield of the final product which is a piperazine prodrug useful as an antiviral.Type: ApplicationFiled: December 17, 2015Publication date: December 21, 2017Inventors: Michael S. BULTMAN, Benjamin COHEN, Francisco GONZALEZ-BOBES, Matthew R. HICKEY
-
Publication number: 20170362263Abstract: In one embodiment, the application discloses ligands, such as a ligand from a dihydrobenzo[1,3] oxaphosphole scaffold, and palladium complexes comprising the ligands and methods for performing cross coupling reactions and asymmetric cross coupling reactions with high selectivity and efficiency.Type: ApplicationFiled: December 9, 2015Publication date: December 21, 2017Applicant: The Regents of the University of CaliforniaInventors: Bruce H. Lipshutz, Sachin Handa
-
Publication number: 20170362264Abstract: Novel phosphorescent tetradentate platinum compounds of Formula I are provided. The complexes contain a dibenzo moiety, which allows for the creation of OLED devices with improved properties when compounds of Formula I are incorporated into such devices. Compounds of Formula I? that comprise two ligands that contain a 5-membered carbocyclic or heterocyclic ring, one of which contains an imidazole ring with a twisted aryl group attached to N?1 and a second aromatic ring that is attached to the platinum via a carbon atom. These compounds may be advantageously used in OLEDs.Type: ApplicationFiled: August 30, 2017Publication date: December 21, 2017Applicant: Universal Display CorporationInventors: Gregg KOTTAS, James FIORDELISO, Bin MA, Chuanjun XIA, Scott BEERS, Jason BROOKS
-
Publication number: 20170362265Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.Type: ApplicationFiled: March 8, 2017Publication date: December 21, 2017Inventors: Chi-Huey WONG, Chung-Yi WU, Sachin S. SHIVATARE
-
Publication number: 20170362266Abstract: The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.Type: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Inventors: Harald C. Ott, Xi Ren, Jordan P. Bloom, Konrad T. Rajab
-
Publication number: 20170362267Abstract: Disclosed are steviol glycosides referred to as rebaudioside V and rebaudioside W. Also disclosed are methods for producing rebaudioside M (Reb M), rebausoside G (Reb G), rebaudioside KA (Reb KA), rebaudioside V (Reb V) and rebaudioside (Reb W).Type: ApplicationFiled: September 7, 2017Publication date: December 21, 2017Applicant: Conagen Inc.Inventors: Guohong Mao, Xiaodan Yu
-
Publication number: 20170362268Abstract: Novel steviol glycoside compounds characterized by a first group of four glucopyranose residues attached via the number 13 carbon (C13) of the steviol moiety and a second group of two or three glucopyranose residues attached via the number 19 carbon (C19) of the steviol moiety are described, and exemplified by compounds 1-4. These compounds can be present in a composition with other steviol glycosides (e.g., Reb D and Reb M) to enhance their solubilities. Accordingly, the novel compounds can facilitate the preparation of aqueous compositions having a higher concentration of steviol glycosides. A steviol glycoside composition including one or more of compounds 1-4 can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) such as foods, beverages, medicines, oral hygiene compositions, nutraceuticals, and the like.Type: ApplicationFiled: December 17, 2015Publication date: December 21, 2017Applicant: Cargill, IncorporatedInventors: Ting Liu Carlson, Dan Gaspard
-
Publication number: 20170362269Abstract: N. gonorrhoeae has become resistant to almost every conventional antibiotic. Described herein is the use of CMP-nonulosonate analogues to counter gonococcal complement evasion. The nonulosonate sugar is incorporated into the lipooligosaccharide of the N. gonorrhoeae which in turn reduces the serum resistance of the bacteria. This provides a novel therapeutic strategy against the global threat of multi-drug resistant gonorrhea.Type: ApplicationFiled: September 1, 2017Publication date: December 21, 2017Applicants: National Research Council of Canada, University of Massachusetts Medical SchoolInventors: Ian SCHOENHOFEN, Dennis M. WHITFIELD, Sanjay RAM
-
Publication number: 20170362270Abstract: Modified oligonucleotides that contain one or more of the phosphate groups substituted at phosphorus and methods for their synthesis are disclosed.Type: ApplicationFiled: August 28, 2014Publication date: December 21, 2017Inventors: Dmitry STETSENKO, Maxim KUPRYUSHKIN, Dmitrii PYSHNYA
-
Publication number: 20170362271Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.Type: ApplicationFiled: May 4, 2017Publication date: December 21, 2017Inventor: Xiangping Qian
-
Publication number: 20170362272Abstract: The present invention provides a novel method for protein manufacture wherein the protein is expressed in a host cell, and in a more specific manner relates to a method for manufacturing a protein that results in reduced levels of product-related impurities.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Inventors: Philip BASSETT, Richard DAVIES, Elena GONZALEZ, Mark PEARCE-HIGGINS
-
Publication number: 20170362273Abstract: Methods of making copolymers are described.Type: ApplicationFiled: October 14, 2014Publication date: December 21, 2017Inventors: Claire Coleman, John Schaeck, Alicia Thompson
-
Publication number: 20170362274Abstract: The present invention relates to peptides enhancing neuronal outgrowth, particularly to peptides that enhance neurite outgrowth and their application.Type: ApplicationFiled: October 20, 2015Publication date: December 21, 2017Inventor: Ying-Chen YANG
-
Publication number: 20170362275Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.Type: ApplicationFiled: August 29, 2017Publication date: December 21, 2017Applicant: Ipsen Pharma S.A.S.Inventor: Zheng Xin DONG
-
Publication number: 20170362276Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: ApplicationFiled: April 3, 2017Publication date: December 21, 2017Applicants: The Administrators of the Tulane Educational Fund, United States Department of Veterans AffairsInventors: James E. ZADINA, Laszlo HACKLER
-
Publication number: 20170362277Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity.Type: ApplicationFiled: August 14, 2017Publication date: December 21, 2017Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster
-
Publication number: 20170362278Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.Type: ApplicationFiled: October 29, 2015Publication date: December 21, 2017Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrea CARFI, Claudio CIFERRI, Irmgard HOFMANN, Holger LAUX, Anders LILJA, Yingxia WEN
-
Publication number: 20170362279Abstract: The disclosure relates to a fusion protein comprising a VP1 binding protein and an exogenous peptide, wherein the exogenous peptide comprises a cargo-securing peptide (CSP) and/or an endosome translocating peptide (ETP) and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.Type: ApplicationFiled: December 8, 2015Publication date: December 21, 2017Applicant: LIFE SCIENCE INKUBATOR BETRIEBS GMBH & CO. KGInventors: SEBASTIAN FRANKEN, ALEXANDER GLASSMANN, NADINE TEMME
-
Publication number: 20170362280Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.Type: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Inventors: Thierry-Thien NGUYEN, Mark BRUNER
-
Publication number: 20170362281Abstract: The invention relates to mutant NQ-Rhodopsin having potassium pumping properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.Type: ApplicationFiled: December 23, 2015Publication date: December 21, 2017Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V., FORSCHUNGSZENTRUM JUELICH GMBH, CEA COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVESInventors: Ernst BAMBERG, Christian BAMANN, Vitaly POLOVINKIN, Valentin GORDELIY, Vitaly SHEVCHENKO, Ivan GUSHCHIN
-
Publication number: 20170362282Abstract: The present disclosure provides compositions and methods for preparing engineered porous protein crystals comprising at least one guest molecule.Type: ApplicationFiled: June 20, 2017Publication date: December 21, 2017Applicant: Colorado State University Research FoundationInventors: Christopher D. Snow, Thaddaus R. Huber
-
Publication number: 20170362283Abstract: The invention relates to new antimicrobial compounds derived from nisin. In particular, the compounds are based on the unsubstituted nisin [1-12] structure, wherein said compounds have an antimicrobial activity exceeding the activity of the unsubstituted nisin [1-12] structure.Type: ApplicationFiled: January 15, 2016Publication date: December 21, 2017Inventors: Nathaniel Isaac MARTIN, Timo KOOPMANS, Thomas Melvin WOOD, Laurens Henri Johan KLEIJN
-
Publication number: 20170362284Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: ApplicationFiled: June 16, 2017Publication date: December 21, 2017Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
-
Publication number: 20170362285Abstract: The present invention relates to the field of fungal biotechnology, more particularly to genetic engineering methods for the production of carotenoids in fungal hosts selected from Rhodospordium and Rhodotorula genera.Type: ApplicationFiled: December 14, 2015Publication date: December 21, 2017Applicant: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Yanbin LIU, Chong Mei KOH, Lianghui JI
-
Publication number: 20170362286Abstract: Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X?4 is D, E or other negatively-charged amino acid or derivative thereof, X?3 is E, I, L, S, V, W or a tryptophan derivative, X?2 is any amino acid, X?1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.Type: ApplicationFiled: August 14, 2015Publication date: December 21, 2017Inventors: Raymond S. NORTON, Shih Chieh CHANG, Michael W. PENNINGTON, Christine BEETON, Brian J. SMITH
-
Publication number: 20170362287Abstract: Isolated GPC3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce GPC3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, hepatocellular carcinoma and melanoma.Type: ApplicationFiled: December 4, 2015Publication date: December 21, 2017Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: YASUHARU NISHIMURA, YUSUKE TOMITA, RYUJI OSAWA
-
Publication number: 20170362288Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.Type: ApplicationFiled: June 26, 2017Publication date: December 21, 2017Inventor: Xue-Ping WANG
-
Publication number: 20170362289Abstract: A method of making a synthetic foldable having a tertiary structure emulating the tertiary structure of a reference foldable protein is described. The method includes determining a folding nucleus peptide sequence associated with folding the reference foldable protein. The synthetic foldable protein is synthesized by including the determined folding nucleus peptide sequence and at least one repeat thereof in the peptide sequence of the synthetic foldable protein.Type: ApplicationFiled: September 7, 2017Publication date: December 21, 2017Applicant: Florida State University Research Foundation, Inc.Inventors: Michael Blaber, Liam M. Longo